{
    "paper_id": "PMC7123826",
    "metadata": {
        "title": "Cryptococcosis",
        "authors": [
            {
                "first": "Misha",
                "middle": [],
                "last": "Rosenbach",
                "suffix": "",
                "email": "Misha.Rosenbach@uphs.upenn.edu",
                "affiliation": {}
            },
            {
                "first": "Karolyn",
                "middle": [
                    "A."
                ],
                "last": "Wanat",
                "suffix": "",
                "email": "karolyn-wanat@uiowa.edu",
                "affiliation": {}
            },
            {
                "first": "Robert",
                "middle": [
                    "G."
                ],
                "last": "Micheletti",
                "suffix": "",
                "email": "robert.micheletti@uphs.upenn.edu",
                "affiliation": {}
            },
            {
                "first": "Laura",
                "middle": [
                    "A."
                ],
                "last": "Taylor",
                "suffix": "",
                "email": "Laura.Taylor@uphs.upenn.edu",
                "affiliation": {}
            },
            {
                "first": "Amy",
                "middle": [
                    "K."
                ],
                "last": "Forrestel",
                "suffix": "",
                "email": "amy.forrestel@uphs.upenn.edu",
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "\nInfection with encapsulated yeast or gattii\n\nC. neoformans is found in bird and bat droppings and contaminated soil/dust; C. gattii colonizes trees/wood debris\nInfection typically occurs following inhalation leading to variable pulmonary manifestations (ranging from asymptomatic mild pneumonitis to acute respiratory distress syndrome (ARDS))The majority of cases will remain contained within the lungsReactivation can occur when immunosuppression prevents continued proper containment of a latent infection\nCutaneous lesions almost always result from embolic hematogenous spread in disseminated diseaseApproximately 10% of cryptococcal infections will become disseminated, typically occurring in immunocompromised patients (HIV/AIDS, chemotherapy, organ transplant, chronic steroid use); dissemination rates may reach up to 50% in AIDS patients, often occurring when CD4 counts are below 50\u2013100/\u03bcLIn patients with disseminated disease, hematogenous spread leads to CNS (70\u201390%) and skin (10\u201315%) involvement most commonly\nPrimary cutaneous cryptococcosis is very rare following direct innoculation; skin involvement should lead one to suspect and evaluate for systemic disease in all cases\n",
            "cite_spans": [],
            "section": "Overview",
            "ref_spans": []
        },
        {
            "text": "\nSevere mengingo-encephalitis in immunocompromised patients is the most common clinical presentation of disseminated disease; most mycotic meningitis cases are secondary to cryptococcosisPatients commonly experience fever, headache, and meningeal signsFatal if untreated; so a high index of suspicion is necessary\n\nSymptomatology is based on the distribution of disseminated disease and can include lymph nodes, skin, eye, kidney, bones, etc.In disseminated disease cutaneous lesions are most commonly found on the head and neck and may present as umbilicated or crateriform nodules, indurated or soft plaques, ulcers, blisters, tumor-like masses, or draining sinusesMolluscum-like papules with central umbilication, acneiform pustules, and Kaposi sarcoma-like lesions can be seen in AIDS patients.\n\nCyrptococcal cellulitis is seen in severely immunocompromised hosts and has an abrupt onset of red-brown erythema with rapid progressionIn primary cryptococcosis lesions may be ulcers, nodules, abscesses, or plaques favoring exposed areas at the site of prior skin trauma with local adenopathy (Fig. 43.1)\n\n\n",
            "cite_spans": [],
            "section": "Clinical Presentation",
            "ref_spans": [
                {
                    "start": 1100,
                    "end": 1104,
                    "mention": "43.1",
                    "ref_id": "FIGREF0"
                }
            ]
        },
        {
            "text": "\nPseudoepitheliomatous hyperplasia, acanthosis, or ulceration with gelatinous and/or granulomatous tissue reactions are typical (Fig. 43.2)Gelatinous reactions are associated with an impaired immune response and consist of a high concentration of organisms free in the tissue with minimal associated inflammation/tissue reactionGranulomatous reactions consist of fewer organisms which are mostly located within multinucleated giant cells with a surrounding dense dermal lymphohistiocytic infiltrate\nOrganisms are round to ovoid yeasts (5\u201315 \u03bcm) with a thick-walled spherule with a polysaccharide capsuleThe capsule can be highlighted with mucicarmine (red), methylene blue (purple), alcian blue (purple), or Fontana-Masson/Melanin (dark brown to black) staining\n",
            "cite_spans": [],
            "section": "Histopathology",
            "ref_spans": [
                {
                    "start": 134,
                    "end": 138,
                    "mention": "43.2",
                    "ref_id": "FIGREF1"
                }
            ]
        },
        {
            "text": "\nMolluscum contagiosum : can resemble the umbilicated papular type of crypto; bedside diagnostic testing can show characteristic Hendersson Patterson bodies of the pox-virus, and pathology can distinguish the two\nAcne: most patients with acne will have some comedonal lesions\nHistoplasmosis: varied morphologies and hard to distinguish clinically, biopsy is diagnostic\nCoccidioidomycosis: travel history and biopsy can be helpful\nHerpes simplex virus: clustered vesicles and uniform punched out erosions should prompt evaluation for HSV\nCellulitis: bacterial cellulitis may be more rapidly developing than cryptococcal cellulitis, and should improve on antibiotics; persistent refractory cellulitis, or deeper indurated red-brown cellulitis may prompt evaluation for cryptococcal infection\n",
            "cite_spans": [],
            "section": "Differential Diagnosis",
            "ref_spans": []
        },
        {
            "text": "\nThorough history should elicit potential exposures and immune status (e.g. HIV, chemotherapy use, transplant, etc); physical exam should assess for cutaneous lesions and other symptoms of systemic involvementIn cases of disseminated disease without a known cause of immunosuppression an HIV test should be performed; in patients with known HIV/AIDS a current CD4 count should be obtainedIf suspected pulmonary involvement:Chest X-ray or CT: infiltrates, nodules, pleural effusionsSputum: culture often negative, may need bronchial lavage sent for cryptococcal antigen or open lung or bronchoscopic biopsy\n\nIf suspected CNS involvement:Head CT/MRI: perform prior to lumbar puncture; nodular lesions in basal ganglia, massesLumbar puncture: elevated intracranial pressure, normal cell count or mild pleocytosis (less than 20 cells/\u03bcL with 100% lymphocytes); cryptococcal antigen (CrAg) test on CSF\u2014either latex agglutination (LA), ELISA, or lateral flow assay (LFA) testsIf no access to CrAg testing: India ink smear of CSF, and fungal culture of CSF\n\nEvaluate for other systemic involvement, as appropriate:Serum, urine, pleural fluid, sputum: culture and/or CrAgTissue samples: skin, lung, lymph node, bone marrowOther tests include ESR, CBC, BMP, LFTs, urinalysis\n\n",
            "cite_spans": [],
            "section": "Important Work-Up",
            "ref_spans": []
        },
        {
            "text": "\nConsult infectious disease specialistPlease refer to full protocol recommendations from the Infectious Diseases Society of America and WHO, as dosing and duration of treatment depend on burden of disease, sites of infection, and immune status of patientCNS Involvement:Induction therapy: Amphotericin B + flucytosine for at least 2 weeksConsolidation therapy: fluconazole for minimum 8 weeksMaintenance therapy: fluconazole for at least 6\u201312 months; in HIV at least 12 months and with undetectable viral load and CD4 > 100 cells/\u03bcL (on two separate tests 6 months apart)\nNo CNS Involvement:If cryptococcemia or severe pulmonary disease: Same as CNS diseaseModerate pulmonary disease or single site infection in non-immunosuppressed patient: fluconazole for 6\u201312 months\n\nAntiretroviral Therapy (ART) in HIV-positive patientsCurrent recommendations from the WHO recommend deferring ART initiation in patients with cryptococcal meningitis due to the high risk of IRIS until there is evidence of sustained clinical response to anti-fungal therapy following 2\u20134 weeks of induction and consolidation treatment\n\n",
            "cite_spans": [],
            "section": "Treatment",
            "ref_spans": []
        }
    ],
    "ref_entries": {
        "FIGREF0": {
            "text": "Fig. 43.1: Cryptococcal skin infection: (a) Ulcerated plaque of Cryptococcus with verrucous border in a patient with newly diagnosed HIV/AIDS. (b) Umbilicated papules on the face. (c) Cobblestoned plaque on the shoulder of a patient with disseminated Cryptococcus. (d) Cryptococcus is a rare cause of atypical recalcitrant cellulitis. This tends to be a deeper red-brown with indurated skin, as shown here in a heart transplant recipient who developed cryptococcal cellulitis with disseminated infection.",
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Fig. 43.2: Cryptococcus (2.5\u00d7, 20\u00d7; H&E\n40\u00d7; Grocott): (a) Acute and chronic inflammation with neutrophils and histiocytes is characteristic. Some forms may have fewer organisms and more granulomatous inflammation, whereas infections in immunosuppressed hosts may have abundant organisms and appear more mucinous due to the organisms\u2019 capsules. (b) On higher power, there are small spores with surrounding gelatinous walls. (c) Grocott highlights organisms.",
            "type": "figure"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Clinical practice guidelines for the management of cryptoccal disease: 2010 update by the Infectious Diseases Society of America",
            "authors": [
                {
                    "first": "JR",
                    "middle": [],
                    "last": "Perfect",
                    "suffix": ""
                },
                {
                    "first": "WE",
                    "middle": [],
                    "last": "Dismukes",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Dromer",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Clin Infect Dis",
            "volume": "50",
            "issn": "3",
            "pages": "291-322",
            "other_ids": {
                "DOI": [
                    "10.1086/649858"
                ]
            }
        },
        "BIBREF1": {
            "title": "Cryptococcosis",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Negroni",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Clin Dermatol",
            "volume": "30",
            "issn": "6",
            "pages": "599-609",
            "other_ids": {
                "DOI": [
                    "10.1016/j.clindermatol.2012.01.005"
                ]
            }
        },
        "BIBREF2": {
            "title": "",
            "authors": [],
            "year": 2011,
            "venue": "Diagnosis, prevention, and management of cryptococcal disease in HIV-infected adults, adolescents, and children",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        }
    }
}